

To: [redacted] [redacted]@rivm.nl
From: [redacted]
Sent: Sun 1/12/2020 12:21:41 PM
Subject: Fw: [ext] Initial genome release of novel coronavirus - Novel 2019 coronavirus - Virological
Received: Sun 1/12/2020 12:21:53 PM

[Large redacted block]

From: [redacted] <[redacted]@charite.de>

Date: Sunday, 12 January 2020 at 11:50

To: [redacted]@who.int

Cc: "[redacted]" <[redacted]@erasmusmc.nl>, [redacted] <[redacted]@who.int>, "b. nl" <[redacted]@erasmusmc.nl>, [redacted] <[redacted]hk" <[redacted]@hku.hk>, [redacted] <[redacted]@who.int>, [redacted], [redacted] <[redacted]@who.int>, [redacted] <[redacted]@erasmusmc.nl>, [redacted] <[redacted]@hpa.org.uk>, [redacted] <[redacted]@who.int>, [redacted] <[redacted]@who.int>, [redacted] <[redacted]@who.int>, [redacted] <[redacted]@who.int>, [redacted] <[redacted]@who.int>, [redacted] <[redacted]@who.int>, [redacted] <[redacted]@who.int>, [redacted] <[redacted]@charite.de>

Subject: Re: [ext] Initial genome release of novel coronavirus - Novel 2019 coronavirus - Virological

Our assays perfectly match all newly released sequences.

[redacted]
Institute of Virology
Charite Campus Mitte
Berlin
iPhone

[Large redacted block]

On 12 Jan 2020, at 10:46, [redacted] <[redacted]@erasmusmc.nl> wrote:
Yes, [redacted] we are looking at it. We need to know if there is possible technical issues (sequences generated on different platforms and analysed with different software packages), but if confirmed the

< 5.1.2e @who.int>, " 5.1.2e " < 5.1.2e @who.int>, " 5.1.2e "
< 5.1.2e @who.int>

Betreff: Re: [ext] Initial genome release of novel coronavirus - Novel 2019 coronavirus - Virological

dear all,

Just received the information from [redacted] 5.1.2e will release their sequence tomorrow morning. According to what she mailed the sequence is somewhat different:

5.1.2| Concept

So maybe it does not affect the primer design, but not sure....

best regards

5.1.2e

Van: 5.1.2e ; 5.1.2e @hku.hk>

Verzonden: zaterdag 11 januari 2020 15:35:31

Aan: [redacted] 5.1.2e ; [redacted] 5.1 ; [redacted] 5.1.2e ; [redacted] 5.1.2e ; [redacted] 5.1.2e ;

CC: [redacted] 5.1.2e ; [redacted] 5.1.2e ; [redacted] 5.1.2e ; [redacted] 5.1.2e ; [redacted] 5.1.2e ; [redacted] 5.1.2e ;

Onderwerp: Re: [ext] Initial genome release of novel coronavirus - Novel 2019 coronavirus - Virological

Hi [redacted] 5.1.2e

We are also happy to participate.

Best wishes

5.1.2e

From: [redacted] 5.1.2e < [redacted] 5.1.2e @erasmusmc.nl >

Sent: Saturday, January 11, 2020 16:07

To: [redacted] 5.1.2e ; [redacted] 5.1 ; [redacted] 5.1.2e ; [redacted] 5.1.2e ; [redacted] 5.1.2e ; [redacted] 5.1.2e ;

Cc: [redacted] 5.1.2e ; [redacted] 5.1.2e ; [redacted] 5.1.2e ; [redacted] 5.1.2e ; [redacted] 5.1.2e ; [redacted] 5.1.2e ; [redacted] 5.1.2e ;

Subject: Re: [ext] Initial genome release of novel coronavirus - Novel 2019 coronavirus - Virological

Excellent, same here!

[redacted] 5.1.2e as discussed yesterday with [redacted] 5.1.2e we are in.

5.1.2e
5.1.2e
Erasmus MC
Wytemaweg 80 - room 5.1.2e
3015 CN Rotterdam

Tel: 00 5.1.2e
Fax: 00 5.1.2e
Email: 5.1.2e @erasmusmc.nl

Van: 5.1.2e <5.1.2e @charite.de>

Verzonden: zaterdag 11 januari 2020 08:43:41

Aan: 5.1.2e ; 5.1.2e ; 5.1.2e ; 5.1.2e ; 5.1.2e ;

5.1.2e ; 5.1.2e ; 5.1.2e

CC: 5.1.2e ; 5.1.2e 5.1.2e ; 5.1.2e ; 5.1.2e

5.1.2e 5.1.2e 5.1.2e ; 5.1.2e ; 5.1.2e ; 5.1.2e

Onderwerp: Re: [ext] Initial genome release of novel coronavirus - Novel 2019 coronavirus - Virological

Dear All,

This is great news.

Based on bat-CoV genome alignments, we have made diagnostic PCR candidates last week. They are already in our lab and are undergoing technical validation over the weekend (signal strength, chemical stability, end point sensitivity based on preliminary synthetic templates). Several of these candidates match the Wuhan virus perfectly. We will release the best candidates to the group once they have passed our technical pre-evaluation. We will then do a quick but comprehensive clinical evaluation similar to what we did for MERS. We will make Wuhan virus-specific RNA transcripts for use as positive controls and for sensitivity end point studies. Once we have positive controls, we can go public.

Who is interested to participate?

5.1.2e
--

5.1.2e
5.1.2e Institute of Virology
5.1.2e Charité Global Health

Charité - Universitätsmedizin Berlin
Campus Charité Mitte

Chariteplatz 1
D-10117 Berlin
Germany

E-Mail: 5.1.2e @charite.de

5.1.2e

5.1.2e 5.1.2e
5.1.2a

6 - 6

5.1.2a